Cellectis quits CAR-T and pivots to in vivo gene editing
News from BioPharma Dive: Cellectis quits CAR-T and pivots to in vivo gene editing
Cellectis
CLLS $1.44 USD
Cellectis is a French clinical-stage biopharma developing genome-edited CAR-T cell immunotherapies for cancer, pioneering allogeneic off-the-shelf gene-edited CAR T-cells.
Company Info
Recent News
Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
News from Fierce Biotech: Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon